Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma
Yi-Bin Chen, Shuli Li, David C Fisher, Jessica Driscoll, Candice Del Rio, Jeremy Abramson, Philippe Armand, Jeffrey Barnes, Jennifer Brown, Corey Cutler, Areej El-Jawahri, Vincent T Ho, Ephraim Hochberg, Steven McAfee, Ronald Takvorian, Thomas R Spitzer, Joseph H Antin, Robert Soiffer, Eric Jacobsen, Yi-Bin Chen, Shuli Li, David C Fisher, Jessica Driscoll, Candice Del Rio, Jeremy Abramson, Philippe Armand, Jeffrey Barnes, Jennifer Brown, Corey Cutler, Areej El-Jawahri, Vincent T Ho, Ephraim Hochberg, Steven McAfee, Ronald Takvorian, Thomas R Spitzer, Joseph H Antin, Robert Soiffer, Eric Jacobsen
Abstract
Many patients with lymphoma relapse after autologous stem cell transplantation (AutoSCT). These patients are often considered for allogeneic stem cell transplantation (AlloSCT) if remission can be achieved. If a tandem approach was organized, some cases of relapse might be prevented. We conducted a phase II trial of tandem AutoSCT followed by reduced-intensity conditioning (RIC) AlloSCT for patients with high-risk lymphoma. High-dose chemotherapy was given with busulfan, cyclophosphamide, and etoposide. AlloSCT was composed of RIC with busulfan/fludarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Donors were fully matched related or unrelated donors. AlloSCT was performed any time between 40 days and 6 months after AutoSCT. Forty-two patients were enrolled, and all patients underwent AutoSCT. RIC AlloSCT was performed in 29 patients. In the 29 patients who underwent tandem transplant, median time from AutoSCT to AlloSCT was 96 days (range, 48 to 169). The 6-month cumulative incidence of grades II to IV acute GVHD was 13.8% (90% confidence interval [CI], 5.3% to 26.3%). Cumulative incidence of chronic GVHD at 1 year was 37.9% (90% CI, 23.1% to 52.7%). Nonrelapse mortality at 2 years after AlloSCT was 11.1% (90% CI, 3.5% to 23.6%). At a median follow-up of 30 months (range, 17.1 to 51.5) for the entire group, the 2-year progression-free survival rate was 64% (90% CI, 50% to 75%) and the 2-year overall survival rate was 69% (90% CI, 43% to 85%). For the 29 patients who underwent tandem SCT, the 2-year progression-free survival rate was 72% (90% CI, 55% to 83%) and the 2-year OS rate was 89% (90% CI, 74% to 96%). Tandem AutoSCT-RIC AlloSCT appears to be safe and effective in patients with high-risk lymphoma. Prospective trials using such an approach in specific lymphoma subtypes are warranted.
Keywords: Auto-allo; Lymphoma; Reduced-intensity conditioning; Tandem transplant.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Source: PubMed